These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 33682725)

  • 21. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
    Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
    Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
    Mestre TA; Pont-Sunyer C; Kausar F; Visanji NP; Ghate T; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Kasten M; Wadia PM; Zadikoff C; Kumar P; de Bie RM; Thomsen T; Lang AE; Schüle B; Klein C; Tolosa E; Marras C
    Mov Disord; 2018 Jul; 33(6):960-965. PubMed ID: 29665080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Motor subtypes and clinical characteristics in sporadic and genetic Parkinson's disease groups: analysis of the PPMI cohort.
    Jeong EH; Lee JY; Han SK; Song YS
    Front Neurol; 2023; 14():1276251. PubMed ID: 37954645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease.
    Arora S; Visanji NP; Mestre TA; Tsanas A; AlDakheel A; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Lang AE; Little MA; Marras C
    J Parkinsons Dis; 2018; 8(4):503-510. PubMed ID: 30248062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher urate in LRRK2 mutation carriers resistant to Parkinson disease.
    Bakshi R; Macklin EA; Logan R; Zorlu MM; Xia N; Crotty GF; Zhang E; Chen X; Ascherio A; Schwarzschild MA
    Ann Neurol; 2019 Apr; 85(4):593-599. PubMed ID: 30761591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson's Disease: Longitudinal Data from the PPMI Study.
    Koros C; Simitsi AM; Papagiannakis N; Bougea A; Prentakis A; Papadimitriou D; Pachi I; Beratis I; Stanitsa E; Angelopoulou E; Antonelou R; Bregianni M; Lourentzos K; Papageorgiou SG; Bonakis A; Trapali XG; Stamelou M; Stefanis L
    J Parkinsons Dis; 2023; 13(5):811-818. PubMed ID: 37424476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease.
    Wang S; Unnithan S; Bryant N; Chang A; Rosenthal LS; Pantelyat A; Dawson TM; Al-Khalidi HR; West AB
    Mov Disord; 2022 Jul; 37(7):1454-1464. PubMed ID: 35521944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.
    Dzamko N; Rowe DB; Halliday GM
    Mov Disord; 2016 Jun; 31(6):889-97. PubMed ID: 26917005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum uric acid level as a putative biomarker in Parkinson's disease patients carrying GBA1 mutations: 2-Year data from the PPMI study.
    Koros C; Simitsi AM; Papagiannakis N; Bougea A; Prentakis A; Papadimitriou D; Pachi I; Antonelou R; Angelopoulou E; Beratis I; Bozi M; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    Parkinsonism Relat Disord; 2021 Mar; 84():1-4. PubMed ID: 33508700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biochemical markers for severity and risk in GBA and LRRK2 Parkinson's disease.
    Thaler A; Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Shenhar-Tsarfaty S; Mirelman A
    J Neurol; 2021 Apr; 268(4):1517-1525. PubMed ID: 33388928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Features of LRRK2 Carriers with Parkinson's Disease.
    Kestenbaum M; Alcalay RN
    Adv Neurobiol; 2017; 14():31-48. PubMed ID: 28353277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolomic profiling in LRRK2-related Parkinson's disease.
    Johansen KK; Wang L; Aasly JO; White LR; Matson WR; Henchcliffe C; Beal MF; Bogdanov M
    PLoS One; 2009 Oct; 4(10):e7551. PubMed ID: 19847307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sensor-based gait analysis in the premotor stage of LRRK2 G2019S-associated Parkinson's disease.
    Sánchez-Rodríguez A; Tirnauca C; Salas-Gómez D; Fernández-Gorgojo M; Martínez-Rodríguez I; Sierra M; González-Aramburu I; Stan D; Gutierrez-González A; Meissner JM; Andrés-Pacheco J; Rivera-Sánchez M; Sánchez-Peláez MV; Sánchez-Juan P; Infante J
    Parkinsonism Relat Disord; 2022 May; 98():21-26. PubMed ID: 35421781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.
    Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mild cognitive impairment among LRRK2 and GBA1 patients with Parkinson's disease.
    Thaler A; Livne V; Rubinstein E; Omer N; Faust-Socher A; Cohen B; Giladi N; Shirvan JC; Cedarbaum JM; Gana-Weisz M; Goldstein O; Orr-Urtreger A; Alcalay RN; Mirelman A
    Parkinsonism Relat Disord; 2024 Jun; 123():106970. PubMed ID: 38691978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are LRRK2 p.G2019S or GBA1 variants associated with long-term outcomes of deep brain stimulation for Parkinson's disease?
    Anis S; Goldberg T; Shvueli E; Kozlov Y; Redlich Y; Lavi N; Lavie I; Sosero YL; Gan-Or Z; Ungar L; Zibly Z; Greenbaum L; Fay-Karmon T; Hassin-Baer S
    Parkinsonism Relat Disord; 2024 Jul; 124():106008. PubMed ID: 38242744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of association between LRRK2 G2385R and cognitive dysfunction in Korean patients with Parkinson's disease.
    Hong JH; Kim YK; Park JS; Lee JE; Oh MS; Chung EJ; Kim JY; Sung YH; Lyoo CH; Lee JH; Kwon DY; Kim HS; Shin HW; Park SA; Park IS; Kim JS; Lee PH; Koh SB; Baik JS; Kim SJ; Ma HI; Kim JW; Kim YJ
    J Clin Neurosci; 2017 Feb; 36():108-113. PubMed ID: 27839916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.
    Somme JH; Molano Salazar A; Gonzalez A; Tijero B; Berganzo K; Lezcano E; Fernandez Martinez M; Zarranz JJ; Gómez-Esteban JC
    Parkinsonism Relat Disord; 2015 May; 21(5):494-9. PubMed ID: 25840672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Total Bilirubin with Motor Signs in Early Parkinson's Disease in LRRK2 Variant Carriers.
    Kazemi D; Hajishah H; Chadeganipour AS
    J Mol Neurosci; 2022 Nov; 72(11):2338-2344. PubMed ID: 36125733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.